azd5055 + rabeprazole

AZD5055 + rabeprazole is a combination used in clinical pharmacokinetic studies, primarily to assess the effect of rabeprazole (a proton pump inhibitor) on the pharmacokinetics of AZD5055. AZD5055 is a potent, selective, oral small molecule inhibitor of Porcupine, a membrane-bound O-acyltransferase critical for activation of Wnt ligands in the Wnt signaling pathway. The combination does not represent a marketed combination drug but is used experimentally to characterize AZD5055’s absorption under conditions of reduced gastric acidity induced by rabeprazole. AZD5055 is under development for idiopathic pulmonary fibrosis and potentially other Wnt-driven fibrotic diseases and cancers, with rabeprazole being used as a tool to assess AZD5055’s pharmacokinetics in the context of acid-reducing agents.

Other names

rabeprazole